COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01337583
Recruitment Status : Withdrawn
First Posted : April 19, 2011
Last Update Posted : June 11, 2012
Information provided by:
International Partnership for Microbicides, Inc.

Brief Summary:
This is a double-blind, randomized, placebo-controlled Phase III study to asses the safety and efficacy of a silicone elastomer vaginal ring containing 25mg of dapivirine.

Condition or disease Intervention/treatment Phase
HIV Infections Other: Dapivirine Other: Placebo Drug: Dapivirine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women
Study Start Date : July 2011
Estimated Primary Completion Date : July 2014
Estimated Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Dapivirine
Vaginal ring containing 25mg of dapivirine
Other: Dapivirine
Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months

Drug: Dapivirine
Placebo Comparator: Placebo Ring
Vaginal ring containing no drug substance
Other: Placebo
Vaginal Ring containing no drug substance

Primary Outcome Measures :
  1. Efficacy as determined by HIV-1 seroconversion rate per person-years of product use, measured at the end of the investigational product use period. [ Time Frame: 15 months ]
    The primary endpoint is HIV-1 seroconversion measured by rapid and specialized laboratory tests according to a comprehensive HIV testing algorithm. This algorithm employs a series of high specificity and high sensitivity immunoassay-based HIV blood tests that minimize the chance of false positive results to determine if a subject is positive for HIV. Endpoint confirmation of HIV infection is by Western blot.

  2. Safety as determined by grade 3 and 4 AE's, clinically significant grade 2 laboratory findings (based on DAIDS grading) and all serious AE's. [ Time Frame: 15 months ]
    This will be measured by self-reports, physical examination, safety laboratory tests and other specialised investigations.

Secondary Outcome Measures :
  1. Adherence to the protocol-specific product regimen as determined by self-reported diary cards and questionnaires. [ Time Frame: 15 months ]
  2. The incidence of curable STI's or pregnancy as determined by STI testing and pregnancy testing. [ Time Frame: 15 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women >18 and <40 years of age who can provide informed consent
  • Available for all visits and consent to follow all procedures scheduled for the trial
  • Generally healthy and self-reported sexually active (defined as an average of at least one penetrative penile vaginal coital act per month for the last 3 months prior to enrolment)
  • HIV-negative as determined by the HIV algorithm applied at screening and enrolment
  • On a stable form of contraception and willing to continue on stable contraception for the duration of the clinical trial;
  • Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any clinically significant treatable STI, she must have initiated treatment at least 1 week prior to enrolment and have completed the full course of treatment)
  • Willing to answer questions about adherence, sexual behaviour, vaginal practices and ring acceptability;
  • Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures (e.g., by home visit or telephone; or via family or close neighbour contacts [confidentiality to be maintained])
  • Willing to refrain from participation in another research trial using drugs, vaccines, medical devices, microbicides or oral pre-exposure prophylaxis investigational drugs for the duration of the IPM 009B trial;
  • In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 35 days between menses;
  • Willing to refrain from use of vaginal products or objects including spermicides, tampons, female condoms, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches and drying agents within 14 days from enrolment and for the duration of the trial.

Exclusion Criteria:

  • Currently pregnant or last pregnancy within 3 months prior to screening;
  • Currently breast-feeding
  • Participated in another research trial using drugs, medical devices, microbicides or oral pre-exposure prophylaxis agents within 60 days prior to screening
  • Previously participated or currently participating in any HIV vaccine trial
  • Untreated, clinically significant urogenital infections (either symptomatic or asymptomatic), e.g., urinary tract or other sexually transmitted infections, or other gynaecological symptoms within 1 week prior to enrolment
  • History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence
  • Any gynaecological surgery within 90 days prior to enrolment
  • Any Grade 3 or 4 baseline haematology, chemistry or urinalysis laboratory value according to the DAIDS Table for Grading Adverse Experiences, or clinically significant Grade 2 findings
  • Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or a silicone elastomer
  • Any history of diabetes mellitus and chronic use of oral steroid therapy and any uncontrolled serious chronic or progressive disease
  • Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation [this includes any findings of atypical squamous cells of undetermined significance (ASCUS)]
  • Any condition(s) that, in the opinion of the investigator, might put the participant at risk, or interfere with the trial objectives, or adherence to trial requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01337583

Layout table for location information
Suba District Hospital
Mbita, Kenya
University of North Carolina Project
Lilongwe, Malawi
South Africa
Desmond Tutu HIV Foundation, Nyanga (DTHF)
Nyanga, Cape Town, South Africa
Prevention of HIV / AIDS (PHIVA) Project
Pinetown, KwaZulu Natal, South Africa, 3610
Maternal, Adolescent and Child Health (MatCH)
Plessislaer, South Africa, 3216
Sponsors and Collaborators
International Partnership for Microbicides, Inc.
Layout table for investigator information
Study Director: Annalene Nel IPM
Layout table for additonal information
Responsible Party: Annalene Nel, MBChB, PhD, International Partnership for Microbicides, Inc. Identifier: NCT01337583    
Other Study ID Numbers: IPM 009B
First Posted: April 19, 2011    Key Record Dates
Last Update Posted: June 11, 2012
Last Verified: June 2012
Keywords provided by International Partnership for Microbicides, Inc.:
HIV Infections
Anti-HIV agents
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents